132 related articles for article (PubMed ID: 29511030)
1. Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma.
van IJzendoorn DGP; Sleijfer S; Gelderblom H; Eskens FALM; van Leenders GJLH; Szuhai K; Bovée JVMG
Clin Cancer Res; 2018 Jun; 24(11):2678-2687. PubMed ID: 29511030
[No Abstract] [Full Text] [Related]
2. Penile pseudomyogenic hemangioendothelioma/epithelioid sarcoma-like hemangioendothelioma with a novel pattern of SERPINE1-FOSB fusion detected by RT-PCR--report of a case.
Ide YH; Tsukamoto Y; Ito T; Watanabe T; Nakagawa N; Haneda T; Nagai M; Yamanishi K; Hirota S
Pathol Res Pract; 2015 May; 211(5):415-20. PubMed ID: 25749627
[TBL] [Abstract][Full Text] [Related]
3. A novel SERPINE1-FOSB fusion gene results in transcriptional up-regulation of FOSB in pseudomyogenic haemangioendothelioma.
Walther C; Tayebwa J; Lilljebjörn H; Magnusson L; Nilsson J; von Steyern FV; Øra I; Domanski HA; Fioretos T; Nord KH; Fletcher CD; Mertens F
J Pathol; 2014 Apr; 232(5):534-40. PubMed ID: 24374978
[TBL] [Abstract][Full Text] [Related]
4. Expanding the Spectrum of Genetic Alterations in Pseudomyogenic Hemangioendothelioma With Recurrent Novel ACTB-FOSB Gene Fusions.
Agaram NP; Zhang L; Cotzia P; Antonescu CR
Am J Surg Pathol; 2018 Dec; 42(12):1653-1661. PubMed ID: 30256258
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous pseudomyogenic (epithelioid sarcoma-like) haemangioendothelioma FOSB immunohistochemistry demonstrating the SERPINE1-FOSB fusion gene.
Alegría-Landa V; Santonja C; Jo-Velasco M; Kutzner H; Requena L
J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):e550-e552. PubMed ID: 28622428
[No Abstract] [Full Text] [Related]
6. FOSB is a Useful Diagnostic Marker for Pseudomyogenic Hemangioendothelioma.
Hung YP; Fletcher CD; Hornick JL
Am J Surg Pathol; 2017 May; 41(5):596-606. PubMed ID: 28009608
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
8. A novel SERPINE1-FOSB fusion gene in pseudomyogenic hemangioendothelioma results in activation of intact FOSB and the PI3K-AKT-mTOR signaling pathway and responsiveness to sirolimus.
Ren J; Wang X; Zhou Y; Yue X; Chen S; Ding X; Zeng S; Jiang X; Liu X; Guo Q
J Dermatol; 2021 Dec; 48(12):1900-1906. PubMed ID: 34580903
[TBL] [Abstract][Full Text] [Related]
9. A novel CLTC-FOSB gene fusion in pseudomyogenic hemangioendothelioma of bone.
Bridge JA; Sumegi J; Royce T; Baker M; Linos K
Genes Chromosomes Cancer; 2021 Jan; 60(1):38-42. PubMed ID: 32749039
[TBL] [Abstract][Full Text] [Related]
10. Fusion of the Genes
Panagopoulos I; Lobmaier I; Gorunova L; Heim S
Cancer Genomics Proteomics; 2019; 16(4):293-298. PubMed ID: 31243110
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors.
Steeghs N; Gelderblom H; Wessels J; Eskens FA; de Bont N; Nortier JW; Guchelaar HJ
Invest New Drugs; 2011 Feb; 29(1):137-43. PubMed ID: 19924384
[TBL] [Abstract][Full Text] [Related]
12. ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features.
Antonescu CR; Chen HW; Zhang L; Sung YS; Panicek D; Agaram NP; Dickson BC; Krausz T; Fletcher CD
Genes Chromosomes Cancer; 2014 Nov; 53(11):951-9. PubMed ID: 25043949
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of FOSB immunohistochemistry in pseudomyogenic hemangioendothelioma and its histological mimics.
Sugita S; Hirano H; Kikuchi N; Kubo T; Asanuma H; Aoyama T; Emori M; Hasegawa T
Diagn Pathol; 2016 Aug; 11(1):75. PubMed ID: 27515856
[TBL] [Abstract][Full Text] [Related]
14. Vascular Tumor Recapitulated in Endothelial Cells from hiPSCs Engineered to Express the
van IJzendoorn DGP; Salvatori DCF; Cao X; van den Hil F; Briaire-de Bruijn IH; de Jong D; Mei H; Mummery CL; Szuhai K; Bovée JVMG; Orlova VV
Cell Rep Med; 2020 Dec; 1(9):100153. PubMed ID: 33377124
[TBL] [Abstract][Full Text] [Related]
15. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors.
Langenberg MHG; Witteveen PO; Roodhart J; Lolkema MP; Verheul HMW; Mergui-Roelvink M; Brendel E; Krätzschmar J; Loembé B; Nol-Boekel A; Christensen O; Schellens JHM; Voest EE
Ann Oncol; 2011 Nov; 22(11):2508-2515. PubMed ID: 21378200
[TBL] [Abstract][Full Text] [Related]
17. Diverse clinical presentations of pseudomyogenic hemangioendothelioma associated with EGFL7::FOSB fusion: a second case.
Li B; Zhang C; Zhao L; Chen N; Hu Y; Li Z; Kang S; Blake A; Xiao S
Histopathology; 2024 Mar; 84(4):708-712. PubMed ID: 38012540
[No Abstract] [Full Text] [Related]
18. Clinicopathological study of pseudomyogenic hemangioendothelioma.
Yang N; Huang Y; Yang P; Yan W; Zhang S; Li N; Feng Z
Diagn Pathol; 2023 Feb; 18(1):25. PubMed ID: 36803395
[TBL] [Abstract][Full Text] [Related]
19. Primary pseudomyogenic hemangioendothelioma of right maxilla: a case with immunohistochemistry and FOSB rearrangement study.
Xia RH; Zhu L; Wang LZ; Tian Z; Zhang CY; Hu YH; Gu T; Li J
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Sep; 130(3):e96-e105. PubMed ID: 32035861
[TBL] [Abstract][Full Text] [Related]
20. NR1D1::MAML1 epithelioid and spindle cell sarcoma mimicking pseudomyogenic hemangioendothelioma in core biopsy: A case report and review of the literature.
Warmke LM; Collier CD; Davis JL
Genes Chromosomes Cancer; 2023 Nov; 62(11):655-662. PubMed ID: 37326138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
